This highlights the potential of the IL-33/IL1RL1 axis in modulating IBD susceptibility and the shared inflammatory pathways between IBD and respiratory diseases like asthma (68, 69), suggesting personalized treatment options for IBD patients resistant to certain therapies. Here, IL1RL1 is linked to inflammatory bowel disease.